-
Stocks mostly rise tracking earnings, US-Iran hopes
-
Alarm at German airport after drone found near Ukrainian plane, mid-air incident
-
Pakistan team reaches base camp with body of renowned climber killed in avalanche
-
Salah arrives in Turkey for Trabzonspor talks
-
Ceuta warns of 'unsustainable' situation for child migrants after influx
-
Embattled FIFA chief Infantino holds emergency talks with directors
-
SpaceX rocket stage believed to have slammed into Moon
-
Russian barrage on Kyiv kills 17 as Ukraine fails to down single missile
-
India monsoon floods, landslides kill more than 100 since July: officials
-
'Lost': Migrants despair after Britain expels them back to France
-
South Korea pro baseball league cancels games over heatwave
-
Cathay Pacific's profit soars 71% despite Iran war driving up fuel costs
-
Taiwan probes 17 China-funded firms over high-tech talent poaching
-
Russian barrage on Ukraine kills 15, wounds dozens more
-
Trump warns Iran to open Hormuz or get 'hit very hard'
-
South Korea police raid Starbucks HQ over 'Tank Day' fiasco
-
Factories shed workers in Bangladesh garment sector
-
Tech back in fashion as Asian markets extend rebound
-
North Korea warns of 'military options' over Japan rearmament
-
Total eclipse gives scientists chance to probe Sun's mysteries
-
Tiny light, big dream: Harvesting power from soil in Japan
-
What to know about the total solar eclipse on August 12
-
Trump admin to review 'closed' AI models before release: reports
-
'Like the end of the world': the eclipse chasers flocking to Spain
-
De Minaur fights past Duckworth in all-Aussie Montreal battle
-
Taiwan begins military drills as China pressure grows
-
High bills, cheap panels drive a Philippine solar surge
-
UK mansion where 'listeners' spied on Nazi generals becomes museum
-
Russian barrage on Ukraine kills 2, wounds dozens more
-
Sabalenka tops Uchijima in WTA Toronto opener
-
RE Royalties Announces Third Investment in Solaris Energy's Portfolio and Letter of Intent for Expanded Royalty Partnership for a Further US$62.7 Million
-
Alcaraz withdraws from Cincinnati Masters with wrist injury
-
Kgatlana strikes as South Africa reach WAFCON quarter-finals
-
SpaceX revenue jumps 92% in first earnings report, but shares slide
-
Pakistan close on series-levelling win against West Indies
-
US eyes Hormuz deal 'today or tomorrow' as ship sinks in Red Sea
-
Paramount CEO says politics fueling Warner Bros. merger battle
-
SpaceX revenue jumps 92% in first earnings report
-
Trump's sale of access to Truth Social raises eyebrows
-
New commissioner Berg wants to take MLS to 'next level'
-
SpaceX rocket stage expected to slam into Moon
-
Colombian ex-guerrillas fear for future under hardline president
-
US hopeful Hormuz strait deal will be done 'today or tomorrow'
-
Tsitsipas comeback continues with Montreal first-round win
-
Michigan primary puts Democratic divide on the ballot
-
Swiatek fends off Bejlek to reach Toronto third round
-
South Africa captain Kolisi to make Test return in Argentina
-
Reusser romps to overall lead at Tour de France Femmes
-
Cuba's famed resilience comes at a growing mental cost
-
McDonald's reports slower US sales in 2nd quarter
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
P.Sousa--PC